{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:37:09Z","timestamp":1791844629139,"version":"4.3.4"},"reference-count":255,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union","award":["101061939"],"award-info":[{"award-number":["101061939"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Acquired immunodeficiency syndrome (AIDS) is an enormous global health threat stemming from human immunodeficiency virus (HIV-1) infection. Up to now, the tremendous advances in combination antiretroviral therapy (cART) have shifted HIV-1 infection from a fatal illness into a manageable chronic disorder. However, the presence of latent reservoirs, the multifaceted nature of HIV-1, drug resistance, severe off-target effects, poor adherence, and high cost restrict the efficacy of current cART targeting the distinct stages of the virus life cycle. Therefore, there is an unmet need for the discovery of new therapeutics that not only bypass the limitations of the current therapy but also protect the body\u2019s health at the same time. The main goal for complete HIV-1 eradication is purging latently infected cells from patients\u2019 bodies. A potential strategy called \u201clock-in and apoptosis\u201d targets the budding phase of the life cycle of the virus and leads to susceptibility to apoptosis of HIV-1 infected cells for the elimination of HIV-1 reservoirs and, ultimately, for complete eradication. The current work intends to present the main advantages and disadvantages of United States Food and Drug Administration (FDA)-approved anti-HIV-1 drugs as well as plausible strategies for the design and development of more anti-HIV-1 compounds with better potency, favorable pharmacokinetic profiles, and improved safety issues.<\/jats:p>","DOI":"10.3390\/ijms25073659","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T12:47:11Z","timestamp":1711370831000},"page":"3659","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4847-9711","authenticated-orcid":false,"given":"Belgin","family":"Sever","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskisehir 26470, T\u00fcrkiye"},{"name":"Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan"},{"name":"Department of Drug Discovery, Science Farm Ltd., Kumamoto 862-0976, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-4052","authenticated-orcid":false,"given":"Mikako","family":"Fujita","sequence":"additional","affiliation":[{"name":"Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9796-7669","authenticated-orcid":false,"given":"Halilibrahim","family":"Ciftci","sequence":"additional","affiliation":[{"name":"Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0973, Japan"},{"name":"Department of Drug Discovery, Science Farm Ltd., Kumamoto 862-0976, Japan"},{"name":"Department of Bioengineering Sciences, Izmir Katip Celebi University, Izmir 35620, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"German Advisory Committee Blood (Arbeitskreis Blut), Subgroup \u2018Assessment of Pathogens Transmissible by Blood\u2019 (2016). Human Immunodeficiency Virus (HIV). Transfus. Med. Hemother, 43, 203\u2013222.","DOI":"10.1159\/000445852"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/COH.0000000000000534","article-title":"HIV subtype diversity worldwide","volume":"14","author":"Bbosa","year":"2019","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_3","first-page":"175","article-title":"Combinatorial Strategies for Long-term Control of HIV Infection","volume":"22","author":"Kwon","year":"2020","journal-title":"AIDS Rev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Moranguinho, I., Taveira, N., and B\u00e1rtolo, I. (2023). Antiretroviral Treatment of HIV-2 Infection: Available Drugs Resistance Pathways, and Promising New Compounds. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065905"},{"key":"ref_5","unstructured":"World Health Organization (2023, July 13). HIV and AIDS. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.idc.2019.05.005","article-title":"Management of Advanced HIV Disease","volume":"33","author":"Summers","year":"2019","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Foka, F.E.T., and Mufhandu, H.T. (2023). Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review. Viruses, 15.","DOI":"10.3390\/v15081732"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/hiv.13487","article-title":"Advanced HIV disease: A review of diagnostic and prophylactic strategies","volume":"24","author":"Lehman","year":"2023","journal-title":"HIV Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hiv.12755","article-title":"Planning HIV therapy to prevent future comorbidities: Patient years for tenofovir alafenamide","volume":"20","author":"Shafran","year":"2019","journal-title":"HIV Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev-pathol-050520-112001","article-title":"In Vivo Dynamics of the Latent Reservoir for HIV-1: New Insights and Implications for Cure","volume":"17","author":"Siliciano","year":"2022","journal-title":"Annu. Rev. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.epidem.2017.03.002","article-title":"On the duration of the period between exposure to HIV and detectable infection","volume":"20","author":"Konrad","year":"2017","journal-title":"Epidemics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41572-023-00452-3","article-title":"HIV infection","volume":"9","author":"Bekker","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/02648725.2018.1471641","article-title":"Combating the HIV reservoirs","volume":"34","author":"Church","year":"2018","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"ref_15","first-page":"1507","article-title":"Human Immunodeficiency Viruses: Replication","volume":"49","author":"Knipe","year":"2013","journal-title":"Fields Virology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1742-4690-8-15","article-title":"Retroviral matrix and lipids, the intimate interaction","volume":"8","author":"Muriaux","year":"2011","journal-title":"Retrovirology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1128\/jvi.65.9.5111-5117.1991","article-title":"Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production","volume":"65","author":"Park","year":"1991","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Nagata, S., Imai, J., Makino, G., Tomita, M., and Kanai, A. (2017). Evolutionary Analysis of HIV-1 Pol Proteins Reveals Representative Residues for Viral Subtype Differentiation. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.02151"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Klingler, J., Anton, H., R\u00e9al, E., Zeiger, M., Moog, C., M\u00e9ly, Y., and Boutant, E. (2020). How HIV-1 Gag Manipulates Its Host Cell Proteins: A Focus on Interactors of the Nucleocapsid Domain. Viruses, 12.","DOI":"10.3390\/v12080888"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/pro.3729","article-title":"Structural perspectives on HIV-1 Vif and APOBEC3 restriction factor interactions","volume":"29","author":"Azimi","year":"2020","journal-title":"Protein Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev-virology-101416-041654","article-title":"Making Sense of Multifunctional Proteins: Human Immunodeficiency Virus Type 1 Accessory and Regulatory Proteins and Connections to Transcription","volume":"4","author":"Faust","year":"2017","journal-title":"Annu. Rev. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e64776","DOI":"10.7554\/eLife.64776","article-title":"HIV-1 uncoating by release of viral cDNA from capsid-like structures in the nucleus of infected cells","volume":"10","author":"Zila","year":"2021","journal-title":"eLife"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/COH.0b013e328324bbec","article-title":"The biology of CCR5 and CXCR4","volume":"4","author":"Alkhatib","year":"2009","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"a006924","DOI":"10.1101\/cshperspect.a006924","article-title":"HIV-1 assembly, budding, and maturation","volume":"2","author":"Sundquist","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12977-015-0197-x","article-title":"Evidence that the endosomal sorting complex required for transport-II (ESCRT-II) is required for efficient human immunodeficiency virus-1 (HIV-1) production","volume":"12","author":"Meng","year":"2015","journal-title":"Retrovirology"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kleinpeter, A.B., and Freed, E.O. (2020). HIV-1 Maturation: Lessons Learned from Inhibitors. Viruses, 12.","DOI":"10.3390\/v12090940"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijbiomac.2021.01.076","article-title":"Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs","volume":"172","author":"Tompa","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"eadd7434","DOI":"10.1126\/sciadv.add7434","article-title":"Critical mechanistic features of HIV-1 viral capsid assembly","volume":"9","author":"Gupta","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2215\/CJN.02240218","article-title":"Clinical Pharmacology in HIV Therapy","volume":"14","author":"Atta","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2174\/1568026619666190712204603","article-title":"Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication","volume":"19","author":"Maeda","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"104242","DOI":"10.1016\/j.arabjc.2022.104242","article-title":"The anti-HIV potential of imidazole, oxazole and thiazole hybrids: A mini-review","volume":"15","author":"Deng","year":"2022","journal-title":"Arab. J. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.coph.2020.10.009","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs): A brief overview of clinically approved drugs and combination regimens","volume":"54","author":"Vanangamudi","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(18)31311-4","article-title":"HIV","volume":"392","author":"Ghosn","year":"2018","journal-title":"Lancet"},{"key":"ref_34","first-page":"55","article-title":"Rapid Initiation of Antiretroviral Therapy after HIV Diagnosis","volume":"21","year":"2019","journal-title":"AIDS Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/COH.0000000000000588","article-title":"HIV treatment and prevention 2019: Current standards of care","volume":"15","author":"Phanuphak","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/S2352-3018(16)30015-7","article-title":"Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: A systematic review and meta-analysis","volume":"3","author":"Achhra","year":"2016","journal-title":"Lancet HIV"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/hiv.12534","article-title":"Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: Assessing the evidence","volume":"19","author":"Orkin","year":"2018","journal-title":"HIV Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"603068","DOI":"10.3389\/fphar.2021.603068","article-title":"Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/hiv.13118","article-title":"Tolerability of four-drug antiretroviral combination therapy in primary HIV-1 infection","volume":"22","author":"Burns","year":"2021","journal-title":"HIV Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cpt.1284","article-title":"Modern Human Immunodeficiency Virus Therapy: Progress and Prospects","volume":"105","author":"Flexner","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.drudis.2021.05.008","article-title":"Drug combination therapy for emerging viral diseases","volume":"26","author":"Shyr","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.antiviral.2009.10.007","article-title":"Current status and challenges of antiretroviral research and therapy","volume":"85","author":"Cihlar","year":"2010","journal-title":"Antiviral Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.antiviral.2009.10.016","article-title":"Understanding and managing the adverse effects of antiretroviral therapy","volume":"85","author":"Hawkins","year":"2010","journal-title":"Antiviral Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1744806920927276","DOI":"10.1177\/1744806920927276","article-title":"Chronic Pain in HIV","volume":"16","author":"Addis","year":"2020","journal-title":"Mol. Pain"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11904-020-00486-2","article-title":"Novel Antiretroviral Agents","volume":"17","author":"Cambou","year":"2020","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4149\/av_2020_101","article-title":"HIV-1: Towards understanding the nature and quantifying the latent reservoir","volume":"64","author":"Chatzidimitriou","year":"2020","journal-title":"Acta Virol."},{"key":"ref_47","first-page":"91","article-title":"Antiretroviral therapy interruptions: Impact on HIV treatment and transmission","volume":"10","author":"Dubrocq","year":"2018","journal-title":"HIV AIDS"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Kalidasan, V., and Theva Das, K. (2020). Lessons Learned from Failures and Success Stories of HIV Breakthroughs: Are We Getting Closer to an HIV Cure?. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.00046"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/S2352-3018(18)30059-6","article-title":"HIV treatment in pregnancy","volume":"5","author":"Bailey","year":"2018","journal-title":"Lancet HIV"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/v2020606","article-title":"Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase","volume":"2","author":"Singh","year":"2010","journal-title":"Viruses"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1021\/acs.chemrev.0c00967","article-title":"Avoiding Drug Resistance in HIV Reverse Transcriptase","volume":"121","author":"Cilento","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"104378","DOI":"10.1016\/j.arabjc.2022.104378","article-title":"Current scenario on non-nucleoside reverse transcriptase inhibitors (2018-present)","volume":"15","author":"Deng","year":"2022","journal-title":"Arab. J. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1021\/acs.jmedchem.1c01758","article-title":"Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1517\/14656566.2.12.2065","article-title":"The role of nevirapine in the treatment of HIV-1 disease","volume":"2","author":"Podzamczer","year":"2001","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.virusres.2007.12.018","article-title":"Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase","volume":"134","author":"Ren","year":"2008","journal-title":"Virus Res."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Costa, B., and Vale, N. (2022). Efavirenz: History, Development and Future. Biomolecules, 13.","DOI":"10.3390\/biom13010088"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40262-019-00830-9","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review","volume":"59","author":"Havens","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/jac\/dks404","article-title":"Rilpivirine: A new non-nucleoside reverse transcriptase inhibitor","volume":"68","author":"Sharma","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/COH.0000000000000474","article-title":"Rilpivirine long-acting for the prevention and treatment of HIV infection","volume":"13","author":"Ferretti","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/14656566.2020.1713096","article-title":"Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection","volume":"21","author":"Mu","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/COH.0000000000000471","article-title":"Doravirine: A review","volume":"13","author":"Colombier","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s40265-018-0993-4","article-title":"Doravirine: First Global Approval","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Pham, H.T., Xiao, M.A., Principe, M.A., Wong, A., and Mespl\u00e8de, T. (2020). Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection. Drugs Context, 9.","DOI":"10.7573\/dic.2019-11-4"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3947\/ic.2020.0100","article-title":"An Overview of Human Immunodeficiency Virus-1 Antiretroviral Drugs: General Principles and Current Status","volume":"53","author":"Shin","year":"2021","journal-title":"Infect. Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/17425255.2020.1772755","article-title":"Pharmacokinetics of nucleoside\/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection","volume":"16","author":"Wonganan","year":"2020","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/cmdc.202000695","article-title":"Structure, Synthesis and Inhibition Mechanism of Nucleoside Analogues as HIV-1 Reverse Transcriptase Inhibitors (NRTIs)","volume":"16","author":"Yoshida","year":"2021","journal-title":"ChemMedChem"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1021\/ja020639y","article-title":"An HIV reverse transcriptase-selective nucleoside chain terminator","volume":"125","author":"Fraley","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"ref_68","first-page":"411","article-title":"Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics","volume":"15","author":"Holec","year":"2017","journal-title":"Curr. HIV Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Bianco, M.D.C.A.D., Inacio Leite, D., Silva Castelo Branco, F., Boechat, N., Uliassi, E., Bolognesi, M.L., and Bastos, M.M. (2022). The Use of Zidovudine Pharmacophore in Multi-Target-Directed Ligands for AIDS Therapy. Molecules, 27.","DOI":"10.3390\/molecules27238502"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0000000000001660","article-title":"Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection","volume":"78","author":"Quercia","year":"2018","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1517\/13543784.13.1.55","article-title":"Emtricitabine: A new nucleoside analogue for once-daily antiretroviral therapy","volume":"13","author":"Cahn","year":"2004","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2217\/pgs-2017-0123","article-title":"Precision medicine for HIV: Where are we?","volume":"19","author":"Cusato","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/01.qai.0000137001.40505.56","article-title":"Pharmacokinetic properties of nucleoside\/nucleotide reverse transcriptase inhibitors","volume":"37","author":"Piliero","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.apsb.2021.11.009","article-title":"Approved HIV reverse transcriptase inhibitors in the past decade","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"13596535211067599","DOI":"10.1177\/13596535211067599","article-title":"The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir","volume":"27","author":"Schinazi","year":"2022","journal-title":"Antivir. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1054-3589(07)55008-8","article-title":"HIV-1 protease: Structure, dynamics, and inhibition","volume":"55","author":"Louis","year":"2007","journal-title":"Adv. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.4155\/fmc.13.89","article-title":"Understanding HIV-1 protease autoprocessing for novel therapeutic development","volume":"5","author":"Huang","year":"2013","journal-title":"Future Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.virol.2015.03.021","article-title":"Retroviral proteases and their roles in virion maturation","volume":"479\u2013480","author":"Konvalinka","year":"2015","journal-title":"Virology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"101159","DOI":"10.1016\/j.mam.2022.101159","article-title":"Viral proteases as therapeutic targets","volume":"88","author":"Konvalinka","year":"2022","journal-title":"Mol. Aspects Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e0219821","DOI":"10.1128\/jvi.02198-21","article-title":"The HIV-1 Viral Protease Is Activated during Assembly and Budding Prior to Particle Release","volume":"96","author":"Tabler","year":"2022","journal-title":"J. Virol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1039\/b208248a","article-title":"HIV-1 protease: Mechanism and drug discovery","volume":"1","author":"Brik","year":"2003","journal-title":"Org. Biomol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","article-title":"Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV\/AIDS","volume":"59","author":"Ghosh","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1086\/313853","article-title":"HIV-1 Protease Inhibitors","volume":"30","author":"Eron","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_85","first-page":"95","article-title":"HIV protease inhibitors: A review of molecular selectivity and toxicity","volume":"7","author":"Lv","year":"2015","journal-title":"HIV AIDS"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Weber, I.T., Wang, Y.F., and Harrison, R.W. (2021). HIV Protease: Historical Perspective and Current Research. Viruses, 13.","DOI":"10.3390\/v13050839"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/cmdc.202000101","article-title":"Pharmacokinetic Parameters of HIV-1 Protease Inhibitors","volume":"15","author":"Nascimento","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1089\/apc.2008.0043","article-title":"Intracranial hemorrhage and liver-associated deaths associated with tipranavir\/ritonavir: Review of cases from the FDA\u2019s Adverse Event Reporting System","volume":"22","author":"Struble","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2165\/00003495-200868100-00006","article-title":"Tipranavir: A review of its use in the management of HIV infection","volume":"68","author":"Orman","year":"2008","journal-title":"Drugs"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14656566.2018.1484901","article-title":"Darunavir for the treatment of HIV infection","volume":"19","author":"Spagnuolo","year":"2018","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.2147\/DDDT.S147493","article-title":"Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: Safety and efficacy of a protease inhibitor in the modern era","volume":"12","author":"Squillace","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1083\/jcb.151.2.F9","article-title":"HIV-1 membrane fusion: Targets of opportunity","volume":"151","author":"Doms","year":"2000","journal-title":"J. Cell Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/cmdc.201000289","article-title":"Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41","volume":"5","author":"Cai","year":"2010","journal-title":"ChemMedChem"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.omtn.2018.09.003","article-title":"HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins","volume":"13","author":"Falkenhagen","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Wang, C., Cheng, S., Zhang, Y., Ding, Y., Chong, H., Xing, H., Jiang, S., Li, X., and Ma, L. (2019). Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action. Viruses, 11.","DOI":"10.3390\/v11090811"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Xiao, T., Cai, Y., and Chen, B. (2021). HIV-1 Entry and Membrane Fusion Inhibitors. Viruses, 13.","DOI":"10.3390\/v13050735"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s12551-022-00999-7","article-title":"Membrane attachment and fusion of HIV-1, influenza A, and SARS-CoV-2: Resolving the mechanisms with biophysical methods","volume":"14","author":"Negi","year":"2022","journal-title":"Biophys. Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd1331","article-title":"Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes","volume":"3","author":"Matthews","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP1369","article-title":"Current peptide HIV type-1 fusion inhibitors","volume":"20","author":"Pang","year":"2009","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1126\/science.1241475","article-title":"Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex","volume":"341","author":"Tan","year":"2013","journal-title":"Science"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1128\/JVI.00494-14","article-title":"Stabilizing the native trimer of HIV-1 Env by destabilizing the heterodimeric interface of the gp41 postfusion six-helix bundle","volume":"88","author":"Kesavardhana","year":"2014","journal-title":"J. Virol."},{"key":"ref_103","first-page":"5447","article-title":"Maraviroc: A review of its use in HIV infection and beyond","volume":"9","author":"Woollard","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.str.2010.09.017","article-title":"Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody","volume":"18","author":"Freeman","year":"2010","journal-title":"Structure"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40265-018-0907-5","article-title":"Ibalizumab: First Global Approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e00110-19","DOI":"10.1128\/AAC.00110-19","article-title":"Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection","volume":"63","author":"Beccari","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40265-020-01258-3","article-title":"Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/1060028020942218","article-title":"Ibalizumab: The First Monoclonal Antibody for the Treatment of HIV-1 Infection","volume":"55","author":"Chahine","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection","volume":"382","author":"Kozal","year":"2020","journal-title":"New Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s40265-020-01386-w","article-title":"Fostemsavir: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/14787210.2021.1865801","article-title":"Fostemsavir for the treatment of HIV","volume":"19","author":"Seval","year":"2021","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"113284","DOI":"10.1016\/j.ejmech.2021.113284","article-title":"New drug approvals for 2020: Synthesis and clinical applications","volume":"215","author":"Yuan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/DDDT.S273660","article-title":"Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy","volume":"16","author":"Muccini","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"15910","DOI":"10.1073\/pnas.1002346107","article-title":"Structure-based modeling of the functional HIV-1 intasome and its inhibition","volume":"107","author":"Krishnan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"15137","DOI":"10.1074\/jbc.REV119.006901","article-title":"Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition","volume":"294","author":"Engelman","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1126\/science.aay8015","article-title":"Structural basis for strand-transfer inhibitor binding to HIV intasomes","volume":"367","author":"Passos","year":"2020","journal-title":"Science"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"100044","DOI":"10.1016\/j.crphar.2021.100044","article-title":"Pharmacokinetic drug interactions of integrase strand transfer inhibitors","volume":"2","author":"Lu","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1086\/597290","article-title":"Raltegravir: The first HIV type 1 integrase inhibitor","volume":"48","author":"Hicks","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","article-title":"HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety","volume":"80","author":"Scarsi","year":"2020","journal-title":"Drugs"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3851\/IMP1397","article-title":"Elvitegravir: A new HIV integrase inhibitor","volume":"20","author":"Shimura","year":"2009","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1021\/jm400645w","article-title":"Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S\/GSK1349572) and (S\/GSK1265744)","volume":"56","author":"Johns","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/2040622314530461","article-title":"Dolutegravir: Clinical efficacy and role in HIV therapy","volume":"5","author":"Fantauzzi","year":"2014","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40265-019-01247-1","article-title":"Dolutegravir\/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1177\/1060028020933772","article-title":"Doing More with Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Na\u00efve Adults With HIV-1 Infection","volume":"54","author":"Santevecchi","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fvl-2019-0077","article-title":"Update on HIV integrase inhibitors for the treatment of HIV-1 infection","volume":"14","author":"Max","year":"2019","journal-title":"Future Virol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"103802","DOI":"10.1016\/j.jddst.2022.103802","article-title":"Current status of dolutegravir delivery systems for the treatment of HIV-1 infection","volume":"76","author":"Sarode","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/COH.0000000000000480","article-title":"Cabotegravir: Its potential for antiretroviral therapy and preexposure prophylaxis","volume":"13","author":"Stellbrink","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/14656566.2020.1843635","article-title":"An evaluation of cabotegravir for HIV treatment and prevention","volume":"22","author":"Canetti","year":"2021","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/ajhp\/zxac201","article-title":"Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis","volume":"79","author":"Prather","year":"2022","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/10600280221102532","article-title":"Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis","volume":"57","author":"Durham","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"ref_131","unstructured":"Yu, B., Li, N., and Fu, C. (2007). Privileged Scaffolds in Drug Discovery, Academic Press."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"De Clercq, E., Zhang, Z., Huang, J., Zhang, M., and Li, G. (2023). Biktarvy for the treatment of HIV infection: Progress and prospects. Biochem. Pharmacol., 217.","DOI":"10.1016\/j.bcp.2023.115862"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/jac\/dkaa060","article-title":"Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients","volume":"75","author":"Marcelin","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e167818","DOI":"10.1172\/JCI167818","article-title":"Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model","volume":"133","author":"Bekerman","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Dzinamarira, T., Almehmadi, M., Alsaiari, A.A., Allahyani, M., Aljuaid, A., Alsharif, A., Khan, A., Kamal, M., Rabaan, A.A., and Alfaraj, A.H. (2023). Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection. Medicina, 59.","DOI":"10.3390\/medicina59061041"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1021\/acs.molpharmaceut.3c00626","article-title":"Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent","volume":"20","author":"Subramanian","year":"2023","journal-title":"Mol. Pharm."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"107009","DOI":"10.1016\/j.ijantimicag.2023.107009","article-title":"Lenacapavir: A novel injectable HIV-1 capsid inhibitor","volume":"63","author":"Hitchcock","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12977-021-00583-z","article-title":"Rotten to the core: Antivirals targeting the HIV-1 capsid core","volume":"18","author":"McFadden","year":"2021","journal-title":"Retrovirology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/COH.0000000000000713","article-title":"Lenacapavir: A first-in-class HIV-1 capsid inhibitor","volume":"17","author":"Shaik","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","article-title":"Update and latest advances in antiretroviral therapy","volume":"43","author":"Delgado","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s40265-022-01786-0","article-title":"Lenacapavir: First Approval","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection","volume":"386","author":"DeJesus","year":"2022","journal-title":"New Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/10600280231171375","article-title":"Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV","volume":"58","author":"Tailor","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1021\/ml1000257","article-title":"Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer","volume":"1","author":"Xu","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40121-013-0013-7","article-title":"Cobicistat: A Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase Inhibitors","volume":"2","author":"Nathan","year":"2013","journal-title":"Infect. Dis. Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40265-013-0160-x","article-title":"Cobicistat: A review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection","volume":"74","author":"Deeks","year":"2014","journal-title":"Drugs"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"115172","DOI":"10.1016\/j.ejmech.2023.115172","article-title":"Application and synthesis of thiazole ring in clinically approved drugs","volume":"250","author":"Niu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"13596535211062396","DOI":"10.1177\/13596535211062396","article-title":"The transformation of HIV therapy: One pill once a day","volume":"27","author":"Choudhary","year":"2022","journal-title":"Antivir. Ther."},{"key":"ref_151","first-page":"579","article-title":"The renaissance of fixed dose combinations: Combivir","volume":"3","author":"Portsmouth","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s40265-018-1005-4","article-title":"Dolutegravir\/Rilpivirine: A Review in HIV-1 Infection","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1177\/1060028019831674","article-title":"Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection","volume":"53","author":"Hester","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-018-0896-4","article-title":"Bictegravir: First Global Approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/14656566.2018.1560423","article-title":"Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: Pharmacology and clinical implications","volume":"20","author":"Pham","year":"2019","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.coph.2020.10.005","article-title":"Design strategies for long-acting anti-HIV pharmaceuticals","volume":"54","author":"Sang","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jama.296.7.769","article-title":"Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: A randomized controlled trial","volume":"296","author":"Gulick","year":"2006","journal-title":"JAMA"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/hiv.12716","article-title":"Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch?","volume":"20","author":"Moreno","year":"2019","journal-title":"HIV Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/QCO.0000000000000615","article-title":"Two drugs regimens for HIV","volume":"33","author":"Waters","year":"2020","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/COH.0000000000000708","article-title":"A new paradigm for antiretroviral delivery: Long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV","volume":"17","author":"Bares","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_161","first-page":"20499361221149773","article-title":"Long-acting injectable antiretroviral therapy: Will it change the future of HIV treatment?","volume":"10","author":"Brizzi","year":"2023","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e01526-19","DOI":"10.1128\/JVI.01526-19","article-title":"HIV-1 Matrix Trimerization-Impaired Mutants Are Rescued by Matrix Substitutions That Enhance Envelope Glycoprotein Incorporation","volume":"94","author":"Tedbury","year":"2019","journal-title":"J. Virol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.chom.2021.07.006","article-title":"HIV-1 matrix-tRNA complex structure reveals basis for host control of Gag localization","volume":"29","author":"Muecksch","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"14889","DOI":"10.1073\/pnas.0405596101","article-title":"Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane","volume":"101","author":"Ono","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1083\/jcb.200303200","article-title":"Direct measurement of Gag-Gag interaction during retrovirus assembly with FRET and fluorescence correlation spectroscopy","volume":"162","author":"Larson","year":"2003","journal-title":"J. Cell Biol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.cell.2014.09.057","article-title":"Global changes in the RNA binding specificity of HIV-1 gag regulate virion genesis","volume":"159","author":"Kutluay","year":"2014","journal-title":"Cell"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e02319-16","DOI":"10.1128\/JVI.02319-16","article-title":"Interactions between HIV-1 Gag and Viral RNA Genome Enhance Virion Assembly","volume":"91","author":"Dilley","year":"2017","journal-title":"J. Virol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.jmb.2016.03.005","article-title":"Structural and Molecular Determinants of Membrane Binding by the HIV-1 Matrix Protein","volume":"428","author":"Mercredi","year":"2016","journal-title":"J. Mol. Biol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"E182","DOI":"10.1073\/pnas.1516618113","article-title":"Biochemical evidence of a role for matrix trimerization in HIV-1 envelope glycoprotein incorporation","volume":"113","author":"Tedbury","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1021\/acs.jpcb.9b02655","article-title":"Mechanistic Investigation of HIV-1 Gag Association with Lipid Membranes","volume":"123","author":"Tran","year":"2019","journal-title":"J. Phys. Chem. B"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e58621","DOI":"10.7554\/eLife.58621","article-title":"Binding mechanism of the matrix domain of HIV-1 gag on lipid membranes","volume":"9","author":"Voth","year":"2020","journal-title":"eLife"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Murphy, R.E., and Saad, J.S. (2020). The Interplay between HIV-1 Gag Binding to the Plasma Membrane and Env Incorporation. Viruses, 12.","DOI":"10.3390\/v12050548"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Sumner, C., Kotani, O., Liu, S., Musier-Forsyth, K., Sato, H., and Ono, A. (2022). Molecular Determinants in tRNA D-arm Required for Inhibition of HIV-1 Gag Membrane Binding. J. Mol. Biol., 434.","DOI":"10.1016\/j.jmb.2021.167390"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Socas, L.B.P., and Ambroggio, E.E. (2023). HIV-1 Gag specificity for PIP2 is regulated by macromolecular electric properties of both protein and membrane local environments. Biochim. Biophys. Acta Biomembr., 1865.","DOI":"10.1016\/j.bbamem.2023.184157"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Tomasini, M.D., Johnson, D.S., Mincer, J.S., and Simon, S.M. (2018). Modeling the dynamics and kinetics of HIV-1 Gag during viral assembly. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0196133"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e01567-18","DOI":"10.1128\/mBio.01567-18","article-title":"Identification of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and Maturation","volume":"9","author":"Novikova","year":"2018","journal-title":"mBio"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Chen, S., Xu, J., Liu, M., Rao, A.L.N., Zandi, R., Gill, S.S., and Mohideen, U. (2020). Investigation of HIV-1 Gag binding with RNAs and lipids using Atomic Force Microscopy. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0228036"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1016\/j.bpj.2022.09.027","article-title":"High-speed AFM reveals the dynamics of virus budding","volume":"121","author":"Roos","year":"2022","journal-title":"Biophys. J."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1021\/bi9019274","article-title":"Highly sensitive analysis of the interaction between HIV-1 Gag and phosphoinositide derivatives based on surface plasmon resonance","volume":"49","author":"Anraku","year":"2010","journal-title":"Biochemistry"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Tateishi, H., Anraku, K., Koga, R., Okamoto, Y., Fujita, M., and Otsuka, M. (2014). Design and synthesis of lipid-coupled inositol 1,2,3,4,5,6-hexakisphosphate derivatives exhibiting high-affinity binding for the HIV-1 MA domain. Org. Biomol. Chem., 12.","DOI":"10.1039\/C4OB00350K"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"8957","DOI":"10.1038\/s41598-017-09129-w","article-title":"A clue to unprecedented strategy to HIV eradication: \u201cLock-in and apoptosis\u201d","volume":"7","author":"Tateishi","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Ciftci, H.I., Sierra, R.G., Yoon, C.H., Su, Z., Tateishi, H., Koga, R., Kotaro, K., Yumoto, F., Senda, T., and Liang, M. (2019). Serial Femtosecond X-Ray Diffraction of HIV-1 Gag MA-IP6 Microcrystals at Ambient Temperature. Int. J. Mol. Sci., 20.","DOI":"10.1101\/561100"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"15819","DOI":"10.1038\/s41598-021-95236-8","article-title":"Structural insight into host plasma membrane association and assembly of HIV-1 matrix protein","volume":"11","author":"Ciftci","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Ciftci, H., Sever, B., Ayan, E., Can, M., DeMirci, H., Otsuka, M., TuYuN, A.F., Tateishi, H., and Fujita, M. (2022). Identification of New L-Heptanoylphosphatidyl Inositol Pentakisphosphate Derivatives Targeting the Interaction with HIV-1 Gag by Molecular Modelling Studies. Pharmaceuticals, 15.","DOI":"10.3390\/ph15101255"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cmdc.201200577","article-title":"Identification of a small-molecule inhibitor of HIV-1 assembly that targets the phosphatidylinositol (4,5)-bisphosphate binding site of the HIV-1 matrix protein","volume":"8","author":"Zentner","year":"2013","journal-title":"ChemMedChem"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1074\/jbc.M112.399865","article-title":"Analysis of small molecule ligands targeting the HIV-1 matrix protein-RNA binding site","volume":"288","author":"Alfadhli","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"13722","DOI":"10.1128\/JVI.02271-14","article-title":"Induced maturation of human immunodeficiency virus","volume":"88","author":"Mattei","year":"2014","journal-title":"J. Virol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"10875","DOI":"10.1073\/pnas.191224698","article-title":"Modulation of HIV-like particle assembly in vitro by inositol phosphates","volume":"98","author":"Campbell","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Rica\u00f1a, C.L., and Dick, R.A. (2021). Inositol Phosphates and Retroviral Assembly: A Cellular Perspective. Viruses, 13.","DOI":"10.3390\/v13122516"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12977-021-00571-3","article-title":"Derivation and characterization of an HIV-1 mutant that rescues IP6 binding deficiency","volume":"18","author":"Poston","year":"2021","journal-title":"Retrovirology"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"10417","DOI":"10.1021\/jacs.2c02568","article-title":"Inositol Hexakisphosphate (IP6) Accelerates Immature HIV-1 Gag Protein Assembly toward Kinetically Trapped Morphologies","volume":"144","author":"Pak","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Kleinpeter, A.B., Zhu, Y., Mallery, D.L., Ablan, S.D., Chen, L., Hardenbrook, N., Saiardi, A., James, L.C., Zhang, P., and Freed, E.O. (2023). The Effect of Inositol Hexakisphosphate on HIV-1 Particle Production and Infectivity can be Modulated by Mutations that Affect the Stability of the Immature Gag Lattice. J. Mol. Biol., 435.","DOI":"10.1016\/j.jmb.2023.168037"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.coviro.2021.03.005","article-title":"Integrative structural biology of HIV-1 capsid protein assemblies: Combining experiment and computation","volume":"48","author":"Perilla","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1021\/np50104a008","article-title":"Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids","volume":"57","author":"Fujioka","year":"1994","journal-title":"J. Nat. Prod."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1021\/jm950922q","article-title":"Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents","volume":"39","author":"Kashiwada","year":"1996","journal-title":"J. Med. Chem."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1128\/AAC.45.4.1225-1230.2001","article-title":"Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation","volume":"45","author":"Kanamoto","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"13555","DOI":"10.1073\/pnas.2234683100","article-title":"PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing","volume":"100","author":"Li","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"10957","DOI":"10.1128\/JVI.01369-06","article-title":"In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat)","volume":"80","author":"Adamson","year":"2006","journal-title":"J. Virol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.virol.2006.07.023","article-title":"Determinants of activity of the HIV-1 maturation inhibitor PA-457","volume":"356","author":"Li","year":"2006","journal-title":"Virology"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1128\/JVI.02743-05","article-title":"3-O-(3\u2032,3\u2032-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro","volume":"80","author":"Sakalian","year":"2006","journal-title":"J. Virol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"12095","DOI":"10.1128\/JVI.01626-06","article-title":"Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3\u2019,3\u2019-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag","volume":"80","author":"Zhou","year":"2006","journal-title":"J. Virol."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Stoddart, C.A., Joshi, P., Sloan, B., Bare, J.C., Smith, P.C., Allaway, G.P., Wild, C.T., and Martin, D.E. (2007). Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy\/Liv mice. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0001251"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1128\/AAC.00152-07","article-title":"Phase I and II study of the safety, virologic effect, and pharmacokinetics\/pharmacodynamics of single-dose 3-o-(3\u2032,3\u2032-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection","volume":"51","author":"Smith","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1128\/AAC.01650-08","article-title":"Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1","volume":"53","author":"Salzwedel","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ejmech.2013.01.013","article-title":"Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site","volume":"62","author":"Coric","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1021\/jm3016969","article-title":"New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1","volume":"56","author":"Dang","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1128\/AAC.02560-15","article-title":"Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage","volume":"60","author":"Protack","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsmedchemlett.6b00010","article-title":"Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity","volume":"7","author":"Liu","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1021\/acsmedchemlett.8b00656","article-title":"Second Generation Inhibitors of HIV-1 Maturation","volume":"10","author":"Dicker","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/cid\/cix239","article-title":"Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)","volume":"65","author":"Hwang","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Morales-Ramirez, J., Bogner, J.R., Molina, J.M., Lombaard, J., Dicker, I.B., Stock, D.A., DeGrosky, M., Gartland, M., Pene Dumitrescu, T., and Min, S. (2018). Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir\/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205368"},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Chrobak, E., Marciniec, K., D\u0105browska, A., P\u0119cak, P., B\u0119benek, E., Kadela-Tomanek, M., Bak, A., Jastrz\u0119bska, M., and Boryczka, S. (2019). New Phosphorus Analogs of Bevirimat: Synthesis, Evaluation of Anti-HIV-1 Activity and Molecular Docking Study. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20205209"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"e0187621","DOI":"10.1128\/AAC.01876-21","article-title":"GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile","volume":"66","author":"Dicker","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0022-2836(03)00289-4","article-title":"Antiviral inhibition of the HIV-1 capsid protein","volume":"327","author":"Tang","year":"2003","journal-title":"J. Mol. Biol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jmb.2007.07.070","article-title":"Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein","volume":"373","author":"Kelly","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bmcl.2010.10.131","article-title":"Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly","volume":"21","author":"Fader","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"6643","DOI":"10.1128\/JVI.00493-12","article-title":"Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein","volume":"86","author":"Lemke","year":"2012","journal-title":"J. Virol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1107\/S0907444913006409","article-title":"A novel inhibitor-binding site on the HIV-1 capsid N-terminal domain leads to improved crystallization via compound-mediated dimerization","volume":"69","author":"Lemke","year":"2013","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1016\/j.bmcl.2012.10.034","article-title":"Inhibition of HIV-1 capsid assembly: Optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold","volume":"22","author":"Tremblay","year":"2012","journal-title":"Bioorg Med. Chem. Lett."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1021\/cb400075f","article-title":"Novel inhibitor binding site discovery on HIV-1 capsid N-terminal domain by NMR and X-ray crystallography","volume":"8","author":"Goudreau","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nsmb964","article-title":"A peptide inhibitor of HIV-1 assembly in vitro","volume":"12","author":"Sticht","year":"2005","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1742-4690-10-136","article-title":"Dual-acting stapled peptides target both HIV-1 entry and assembly","volume":"10","author":"Zhang","year":"2013","journal-title":"Retrovirology"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1128\/AAC.00759-09","article-title":"New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation","volume":"53","author":"Blair","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Blair, W.S., Pickford, C., Irving, S.L., Brown, D.G., Anderson, M., Bazin, R., Cao, J., Ciaramella, G., Isaacson, J., and Jackson, L. (2010). HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001220"},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"Dost\u00e1lkov\u00e1, A., \u0160kach, K., Kaufman, F., K\u0159\u00ed\u017eov\u00e1, I., Hadravov\u00e1, R., Flegel, M., Ruml, T., Hrabal, R., and Rumlov\u00e1, M. (2020). PF74 and Its Novel Derivatives Stabilize Hexameric Lattice of HIV-1 Mature-Like Particles. Molecules, 25.","DOI":"10.3390\/molecules25081895"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41591-019-0560-x","article-title":"A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model","volume":"25","author":"Yant","year":"2019","journal-title":"Nat. Med."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.virol.2014.02.021","article-title":"HIV cure research: Advances and prospects","volume":"454\u2013455","author":"Passaes","year":"2014","journal-title":"Virology"},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Dick, A., and Cocklin, S. (2020). Recent Advances in HIV-1 Gag Inhibitor Design and Development. Molecules, 25.","DOI":"10.3390\/molecules25071687"},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Saeb, S., Wallet, C., Rohr, O., Schwartz, C., and Loustau, T. (2023). Targeting and eradicating latent CNS reservoirs of HIV-1: Original strategies and new models. Biochem. Pharmacol., 214.","DOI":"10.1016\/j.bcp.2023.115679"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"e1981","DOI":"10.1002\/rmv.1981","article-title":"Peering into the HIV reservoir","volume":"28","author":"Benito","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1172\/JCI136227","article-title":"The multifaceted nature of HIV latency","volume":"130","author":"Dufour","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/cpt.2187","article-title":"Pharmacology of HIV Cure: Site of Action","volume":"109","author":"Devanathan","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Chen, J., Zhou, T., Zhang, Y., Luo, S., Chen, H., Chen, D., Li, C., and Li, W. (2022). The reservoir of latent HIV. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.945956"},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Ta, T.M., Malik, S., Anderson, E.M., Jones, A.D., Perchik, J., Freylikh, M., Sardo, L., Klase, Z.A., and Izumi, T. (2022). Insights into Persistent HIV-1 Infection and Functional Cure: Novel Capabilities and Strategies. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.862270"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/387183a0","article-title":"Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection","volume":"387","author":"Chun","year":"1997","journal-title":"Nature."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.chom.2020.03.014","article-title":"The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies","volume":"27","author":"Cohn","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virs.2022.01.017","article-title":"Updates on CRISPR-based gene editing in HIV-1\/AIDS therapy","volume":"37","author":"Zhang","year":"2022","journal-title":"Virol. Sin."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1146\/annurev-immunol-080219-023629","article-title":"Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention","volume":"38","author":"Stephenson","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"100073","DOI":"10.1016\/j.jve.2022.100073","article-title":"Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir","volume":"8","author":"Choudhary","year":"2022","journal-title":"J. Virus Erad."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.3389\/fimmu.2018.02861","article-title":"Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ebiom.2019.06.020","article-title":"Deep latency: A new insight into a functional HIV cure","volume":"45","author":"Elsheikh","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"101412","DOI":"10.1016\/j.smim.2020.101412","article-title":"Immunological approaches to HIV cure","volume":"51","author":"Ward","year":"2021","journal-title":"Semin. Immunol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"6952286","DOI":"10.1155\/2022\/6952286","article-title":"Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection","volume":"2022","author":"Bai","year":"2022","journal-title":"Dis. Markers"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2018.07.016","article-title":"Natural product-derived compounds in HIV suppression, remission, and eradication strategies","volume":"158","author":"Andersen","year":"2018","journal-title":"Antiviral Res."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.antiviral.2019.03.008","article-title":"HIV \u201cshock and kill\u201d therapy: In need of revision","volume":"166","author":"Abner","year":"2019","journal-title":"Antiviral Res."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/14712598.2021.1865302","article-title":"HIV-1 cure strategies: Why CRISPR?","volume":"21","author":"Atkins","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_247","doi-asserted-by":"crossref","unstructured":"Thomas, J., Ruggiero, A., Paxton, W.A., and Pollakis, G. (2020). Measuring the Success of HIV-1 Cure Strategies. Front. Cell. Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.00134"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3947\/ic.2021.0136","article-title":"Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention","volume":"53","author":"Kim","year":"2021","journal-title":"Infect. Chemother."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"101478","DOI":"10.1016\/j.smim.2021.101478","article-title":"Shocking HIV-1 with immunomodulatory latency reversing agents","volume":"51","author":"Rodari","year":"2021","journal-title":"Semin. Immunol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1742-4690-11-37","article-title":"HIV-1 protease-induced apoptosis","volume":"11","author":"Ruml","year":"2014","journal-title":"Retrovirology"},{"key":"ref_251","doi-asserted-by":"crossref","unstructured":"Centazzo, M., Manganaro, L., and Alvisi, G. (2023). Cellular Targets of HIV-1 Protease: Just the Tip of the Iceberg?. Viruses, 15.","DOI":"10.20944\/preprints202302.0058.v1"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.chom.2017.12.004","article-title":"Getting the \u201cKill\u201d into \u201cShock and Kill\u201d: Strategies to Eliminate Latent HIV","volume":"23","author":"Kim","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_253","doi-asserted-by":"crossref","unstructured":"Kim, J.G., and Shan, L. (2022). Beyond Inhibition: A Novel Strategy of Targeting HIV-1 Protease to Eliminate Viral Reservoirs. Viruses, 14.","DOI":"10.20944\/preprints202205.0316.v1"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/jmp.12613","article-title":"The role of latency reversal in HIV cure strategies","volume":"51","author":"Tanaka","year":"2022","journal-title":"J. Med. Primatol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"101225","DOI":"10.1016\/j.eclinm.2021.101225","article-title":"Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo","volume":"42","author":"Cummins","year":"2021","journal-title":"EClinicalMedicine"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/7\/3659\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:18:24Z","timestamp":1760105904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/7\/3659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":255,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["ijms25073659"],"URL":"https:\/\/doi.org\/10.3390\/ijms25073659","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]}}}